|1.||Hofer, Stefan: 4 articles (07/2015 - 04/2010)|
|2.||Weigand, Markus A: 3 articles (07/2015 - 04/2010)|
|3.||Schmidt, Karsten: 3 articles (03/2015 - 04/2010)|
|4.||Hur, Gyeung-Haeng: 3 articles (01/2012 - 01/2002)|
|5.||Greig, Nigel H: 3 articles (07/2010 - 02/2005)|
|6.||Wetherell, Janet: 3 articles (04/2007 - 09/2002)|
|7.||Kim, Yun-Bae: 3 articles (11/2005 - 01/2002)|
|8.||Brenner, Thorsten: 2 articles (07/2015 - 01/2015)|
|9.||Lehmann, Christian: 2 articles (04/2015 - 01/2014)|
|10.||Chattopadhyay, Pronobesh: 2 articles (06/2014 - 07/2013)|
02/01/1993 - "Efficacy of physostigmine as a pretreatment for organophosphate poisoning."
01/01/1991 - "This protected enzyme became available as the physostigmine was eliminated from the body after 60-120 min. Animals exhibited mild signs of poisoning, such as hyperactivity and chewing, during the first 30-60 min, after which they recovered. "
03/01/2011 - "Therefore, treatment of OP poisoning with a carbamate, such as physostigmine, should be carefully re-evaluated."
03/01/2011 - "Physostigmine (0.8 mg/kg im) at 1 min after poisoning increased mortality. "
01/01/2009 - "The recommendations of the Swiss Toxicological Information Centre were followed and physostigmine, the antidote for severe poisoning when 10 or more berries are ingested, was not administered. "
|2.||Alzheimer Disease (Alzheimer's Disease)
05/01/1984 - "Subcutaneous or intravenous administration of physostigmine improved the copying of geometric figures in three out of six patients with presumed Alzheimer's disease who showed a remarkable constructional disturbance. "
01/01/1990 - "Along with other studies in the literature, this study casts serious doubt on the efficacy of short-term administration of oral physostigmine when used alone in an attempt to ameliorate cognitive dysfunction in Alzheimer's disease patients. "
01/01/1985 - "To examine the efficacy of cholinergic enhancement in senile dementia of the Alzheimer type (SDAT), oral physostigmine was given to eight patients in a cross-over trial of three dose levels and a matching placebo. "
01/01/1994 - "Physostigmine has been reported to improve the memory function of some patients with Alzheimer's Disease (AD). "
04/01/1993 - "Physostigmine ameliorates the delusions of Alzheimer's disease."
02/01/2002 - "Although physostigmine is considered an acceptable antidote for severe DPH toxicity, adverse effects such as seizures and cholinergic crisis may occur. "
01/01/1990 - "In two infants who had frequent clinical seizures, the seizures were temporarily blocked by physostigmine. "
02/25/1984 - "In six patients seizures were precipitated by physostigmine. "
02/01/1981 - "General supportive care and seizure control with physostigmine resulted in complete recovery within 72 hours. "
01/01/1980 - "dose of physostigmine sulfate (1.0 mg/kg) resulted in 90% mortality among male rats following a pronounced cholinergic syndrome, including convulsions. "
01/01/1985 - "Efficacy of oral physostigmine in primary degenerative dementia. "
01/01/2001 - "All relevant unconfounded, double-blind, randomized, placebo-controlled trials in which physostigmine was administered for more than one day to patients with dementia of Alzheimer type. "
01/01/2001 - "Studies conducted more than 20 years ago suggested that physostigmine could improve memory in people with or without dementia. "
01/01/1990 - "Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial."
01/01/1990 - "Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial."
|5.||Memory Disorders (Memory Loss)
02/01/2008 - "Physostigmine (50 microg/kg) fully reversed memory deficits in the Ts65Dn mice in the 4-month-old group but not in older mice. "
04/01/1985 - "Physostigmine reverses memory deficits produced by pretraining electrical stimulation of the dorsal hippocampus in mice."
04/01/1985 - "Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine."
03/01/1982 - "Physostigmine in the treatment of memory disorders: a case report."
11/01/1992 - "These two drugs had little effect on memory deficits brought about by medial septum or fimbria-fornix lesioning, whereas physostigmine ameliorated these deficits in scopolamine-treated and medial septum-lesioned rats, but not in fimbria-fornix-lesioned rats. "
|9.||Acetylcholine (Acetylcholine Chloride)